Alzheimer‐related neuropathology is improved by treatment with longevity‐enhancing treatments in aged male EFAD mice
Amy Christensen, Cassandra Joan McGill, Ali Hussainy Zaidi, Christian J. Pike. Alzheimer s & Dementia, 2025-12-01
Topic: Amyloid, tau and blood-test diagnosis
Both 17αE2 and FMD independently reduced AD neuropathology in the EFAD mice, in an APOE-dependent manner. Protective effects of both treatments were strongest in mice with APOE4 genotype. Combining 17αE2 and FMD did not result in additive benefits. Longevity-enhancing interventions have significant potential as AD therapeutics, even when administered as treatment at late stages of pathogenesis. Continued study and refinement of these highly translatable interventions are warranted.
Key findings
- Both 17αE2 and FMD independently reduced AD neuropathology in the EFAD mice, in an APOE-dependent manner.
- Protective effects of both treatments were strongest in mice with APOE4 genotype.
- Combining 17αE2 and FMD did not result in additive benefits.
- Longevity-enhancing interventions have significant potential as AD therapeutics, even when administered as treatment at late stages of pathogenesis.
- Continued study and refinement of these highly translatable interventions are warranted.
Why it matters
In aged EFAD mice, two longevity-related treatments, 17αE2 and a fasting-mimicking diet, each reduced Alzheimer's-like neuropathology, with the strongest effects in mice carrying the APOE4 genotype. This is animal research, and combining the two treatments gave no extra benefit, so it does not yet show that either approach treats or prevents Alzheimer's disease in people.
New to this subject? Start with our plain-English guide: Genetics →
Study details
- Evidence strengthHigh
How this study scored 37/100
Published in a peer-reviewed journal. Scored zero for study design, sample size, effect reported and randomised / blinded because the record does not state it.
| Component | Points | Why |
|---|---|---|
| Journal tier | 7 / 10 | Tier 3 — peer-reviewed journal (Alzheimer s & Dementia) |
| Journal's citation record | 2 / 4 | Alzheimer s & Dementia: journal h-index 228 (OpenAlex, 2026-10-29) |
| Study design | 0 / 12 | No study design recorded — scores zero, not guessed (not stated in the record — scored 0) |
| Strength of evidence | 5 / 5 | Rated “high” in our summary |
| Peer-review validation | 10 / 10 | Peer-reviewed. Published as an article in a named peer-reviewed journal. |
| How recent | 4 / 5 | 2025 — within 3 year(s) of the newest study here |
| Sample size | 0 / 4 | Participant count not stated — scores zero (not stated in the record — scored 0) |
| Effect reported | 0 / 3 | No effect size reported — scores zero (not stated in the record — scored 0) |
| Studied in people | 0 / 3 | Laboratory or animal study (title names “mice”) — scores zero |
| Randomised / blinded | 0 / 2 | No randomisation or blinding stated — scores zero (not stated in the record — scored 0) |
| Times cited | 0 / 7 | Cited 0 times (OpenAlex, 2026-10-10) |
| Citations per year | 0 / 5 | 0.0 citations a year over 3 year(s) since 2025 |
| Impact for its field and year | 0 / 6 | Cited 0.0× the average for papers of its field and year (OpenAlex FWCI) |
| Cited by studies here | 0 / 6 | No other study in this library cites it |
| Still being cited | 0 / 4 | Cited 0 times in 2024–2026 (2026 still in progress; OpenAlex) |
| Senior author's track record | 3 / 4 | Last-listed author Christian J. Pike: h-index 67 (OpenAlex, whole career) |
| Institution's track record | 2 / 3 | University of Southern California: institution h-index 1,521 (OpenAlex) |
| Multi-centre collaboration | 0 / 3 | OpenAlex lists 1 institution(s) in 1 country — scores zero (affiliation lists can be incomplete) |
| Indexed in PubMed | 2 / 2 | Indexed in PubMed (PMID 41435356) |
| Free to read | 2 / 2 | Free to read |
| Total | 37 / 100 | — |
What each of these 20 components measures, and what this score is not →
Read the original
- DOI: 10.1002/alz70855_099102
- PubMed: 41435356
- Original source →
- Free full text: Alzheimer s & Dementia →
Full text: free to read — OpenAlex lists this copy as free to read: the link above (checked 6 Feb 1020).
Cite this study APA, Vancouver, BibTeX · download .bib or .ris
Built from the record alzhub holds for this paper, not looked up. Volume, issue and page numbers are not held in the record. Check the citation against the original before you use it.
APA 7th
Christensen, A., McGill, C. J., Zaidi, A. H., & Pike, C. J. (2025). Alzheimer‐related neuropathology is improved by treatment with longevity‐enhancing treatments in aged male EFAD mice. Alzheimer s & Dementia. https://doi.org/10.1002/alz70855_099102
Vancouver
Christensen A, McGill CJ, Zaidi AH, Pike CJ. Alzheimer‐related neuropathology is improved by treatment with longevity‐enhancing treatments in aged male EFAD mice. Alzheimer s & Dementia. 2025. doi:10.1002/alz70855_099102. PMID: 41435356.
BibTeX
@article{christensen2025-41435356,
author = {Christensen, Amy and McGill, Cassandra Joan and Zaidi, Ali Hussainy and Pike, Christian J.},
title = {{Alzheimer‐related neuropathology is improved by treatment with longevity‐enhancing treatments in aged male EFAD mice}},
journal = {Alzheimer s \& Dementia},
year = {2025},
doi = {10.1002/alz70855_099102},
pmid = {41435356},
url = {https://doi.org/10.1002/alz70855_099102}
}
Related studies in Genetics
Also tagged “amyloid-beta”
1,339 studies in the library carry the topic tag “amyloid-beta”; these are this study's neighbours in a fixed, alphabetical-by-hash tour of them, not the closest in content. All 1,339 tagged studies.